OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED)

CAPS Rating: 4 out of 5

Results 1 - 4 of 4

Recs

0
Member Avatar sullyz0r (84.89) Submitted: 5/28/2015 2:20:24 PM : Outperform Start Price: $23.83 OMED Score: -8.48

I'm actually not a huge fan of the "cancer stem cell" hypothesis, but I like this company a lot more for its notch/wnt pathway target pipeline.

Recs

1
Member Avatar Tophinater (< 20) Submitted: 11/17/2014 2:50:42 PM : Outperform Start Price: $20.12 OMED Score: +4.23

i don't know.

Recs

0
Member Avatar manirg (97.98) Submitted: 1/29/2014 12:07:04 PM : Outperform Start Price: $31.42 OMED Score: -48.63

High Risk but has Hugh Potential--5 to 10x. Backed by Celgene.

Recs

0
Member Avatar 5zillion (< 20) Submitted: 7/24/2013 3:40:08 PM : Outperform Start Price: $23.50 OMED Score: -32.64

Got in on tail end of this IPO and paid on the high end. Have to admit I have been biting my fingernails a little bit on this one. I do believe that with patience this one will pay off. With interest from GSK and Bayer I do believe they will be a good investment in due time.

Results 1 - 4 of 4

Featured Broker Partners


Advertisement